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1 
USE OF TR/S-QUATERNARY AMMONIUM 
SALTS AS PAIN MODULATING AGENTS 
FIELD OF THE INVENTION 
The invention relates to the use of tris-quatemary ammo-
nium salts for pain modulation. 
BACKGROUND OF THE INVENTION 
2 
pro fen) act by inhibition of the cyclo-oxygenase (Cox-1 ,2) 
enzyme. They are especially useful in nociceptive pain of 
inflammatory origin (eg. arthritis). However, the NSAID's 
have limited efficacy when compared to the opioids. In addi-
tion, NSAID's have significant side effects (renal, gas-
trointestinal, cardiovascular). The discovery of the Cox-2 
selective agents ( eg. rofecoxib-Vioxx®; celecoxib-Cele-
brex®; valdecoxib-Bextra®) which have far less gastrointes-
tinal toxicity, was thought to be an advance in NSAID phar-
10 macology. Nonetheless, these agents still have low efficacy 
and evidence is now available linking them to significant 
cardiovascular events including stroke and myocardial inf-
arction following chronic use. This has resulted in the 
The treatment of pain is a critical health issue. Acute ( eg. 
postoperative pain) and chronic ( eg. arthritis, low back, can-
cer) pain affects tens of millions of people annually in the US. 
Each year some 30 million people visit a physician with a 
complaint of a painful condition. Some 10% of these patients 
are seen with chronic pain as their main complaint. The finan-
cialloss due to pain has been estimated to exceed 100 billion 
dollars a year as a result of medical fees, decreased produc-
tivity, litigation and the cost of drugs. New therapeutic agents 
with greater efficacy, in particular for chronic neuropathic 20 
pain syndromes ( eg. complex regional pain syndrome), and 
with fewer side effects would result in significant societal 
benefit. 
15 removal of both rofecoxib and valdecoxib from the market. 
No suitable agent exists for the treatment of neuropathic pain. 
GABA-pentin (Neurontin®), an anticonvulsant, has found 
use for some neuropathic pain syndromes ( eg. diabetic 
peripheral neuropathy, postherpetic neuralgia), but it still has 
limited efficacy. Duloxetine (Cymbalta®), an antidepressant, 
has recently been approved for the treatment of diabetic 
peripheral neuropathy. However, it has limited efficacy and 
usefulness for other neuropathic pain states. TheN-methyl-
d-aspartate (NMDA) receptor antagonists (eg. ketamine) Pain can be broadly divided into two categories: nocicep-
tive and neuropathic pain. Nociceptive pain occurs as a result 
of activation of peripheral nociceptors, actually free nerve 
endings by noxious stimuli (heat, pressure, inflannnatory 
mediators). Examples of nociceptive pain include postsurgi-
cal pain, inflammatory pain ( eg. arthritis) and low back pain. 
Such a pain is often described as "a constant, dull, aching 
pain". Neuropathic pain occurs as a result of damage to the 
peripheral or central nervous system. Examples of neuro-
pathic pain include radiculopathy ( eg. disc impingement on a 
nerve), complex regional pain syndrome (CRPS I, II), dia-
betic peripheral neuropathy or central pain (stroke, spinal 
cord injury, multiple sclerosis). Patients typically describe 
neuropathic pain as "burning and tingling" in nature. It is 
characterized by hyperalgesia (increased painful response to 
a noxious stimulus) and allodynia (pain to a previously non-
noxious stimulus). 
In many patients, in particular those with chronic pain 
conditions of malignant (cancer-related pain) and non-malig-
nant (arthritis, low back pain, CRPS) origin, pain is inad-
equately managed with currently available drugs. Available 
drugs are simple modifications ( eg. extended release) of 
drugs from classes which have been available for decades 
including the opioids, nonsteroidal anti-inflammatory agents 
(NSAID's) or various adjuvants (antidepressants, anticonvul-
sants) initially approved for other uses besides pain. Opioids 
( eg. morphine, oxycodone) are often successfully used for the 
treatment of moderate to severe nociceptive pain. Chronic 
neuropathic pain is much less responsive to opioids. Use of 
opioid analgesics is associated with a broad range of signifi-
cant side effects including cognitive impairment, respiratory 
depression and constipation. In addition, long-term opioid 
dosing results in the development of tolerance to the analgesic 
effect, drug abuse and dependence. The NSAID's (eg. ibu-
25 have been proposed for the treatment of neuropathic pain. 
Their general use is impractical given the marked side effects 
including sedation, psychosis and motor impairment. The 
limitations of the currently available therapies clearly dem-
onstrate the need for a broad spectrum new class of effica-
30 cious and safe analgesic drugs for the treatment of nocicep-
tive and neuropathic pain. 
Given the need for more effective, less toxic, analgesic 
drugs, a great deal of emphasis has been placed on identifying 
novel molecular targets that could form the basis for new 
35 analgesics. 
50 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the fol-
lowing structure are provided. 
(I) 
The three side chains attached to the phenyl ring can be 
connected to the 1, 2, and3 positions; the 1, 2, and4 positions; 
or the 1, 3 and 5 positions of the phenyl ring. 
The values for m1, m2 and m3 are each independently 0, 1, 
55 
2, 3, 4 or 5. 
The values for n1, n2, and n3 are each independently 1, 2, 
3, 4 or 5. 
X18, X28, and X38 are each independently an organic or 
inorganic anion. 
L1 , L2 and L3 are each independently chosen from the 
60 group consisting of ---CH2---CH2-, cis -CH=CH-, 
trans ---CH=CH-, -C C-, ---CH2-S-, 
-S-CH2-, -Se-CH2-, ---CH2-Se-, ---CH2---0-, 
---O-CH2-, -CH2-NH-, -NH---CH2-, ---CH2-
NR- where R is a branched or straight chain alkyl group of 
65 one to four carbons, -NR---CH2- where R is a branched or 
straight chain alkyl group of one to four carbons, 
---CH=N-,-N=CH-,and-N N-. 
US 9,155,733 B2 
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R 1 , R 2 , and R3 are each independently five or six membered 
nitrogen containing rings as shown in formulas (IIA) and 
(liB). 
(IIA) 
(liB) 
A 1 is carbon or nitrogen, provided that when A 1 joins a ring 
atom with an unsaturated bond or is a nitrogen, R9 is absent, 
and when A 1 joins a ring atom an unsaturated bond and is a 
nitrogen, both R4 and R9 are absent. 
A 2 is carbon or nitrogen, provided that when A 2 joins a ring 
atom an unsaturated bond or is a nitrogen, R 10 is absent, and 
when A2 joins a ring atom an unsaturated bond and is a 
nitrogen, both Rs and R 10 are absent. 
A3 is carbon or nitrogen, provided that whenA3 joins a ring 
atom an unsaturated bond or is a nitrogen, R 11 is absent, and 
when A3 joins a ring atom an unsaturated bond and is a 
nitrogen, both R 6 and R 11 are absent. 
A 4 is carbon or nitrogen, provided that when A 4 joins a ring 
atom an unsaturated bond or is a nitrogen, R 12 is absent, and 
when A 4 joins a ring atom an unsaturated bond and is a 
nitrogen, both R 7 and R 12 are absent. 
As is carbon or nitrogen, provided thatwhenAs joins a ring 
atom an unsaturated bond or is a nitrogen, R 13 is absent, and 
when As joins a ring atom an unsaturated bond and is a 
nitrogen, both R 8 and R 13 are absent. 
A 6 is carbon or nitrogen, provided that when A 6 joins a ring 
atom an unsaturated bond or is a nitrogen, R 19 is absent, and 
when A6 joins a ring atom an unsaturated bond and is a 
nitrogen, both R Is and R 19 are absent. 
A 7 is carbon or nitrogen, provided that when A 7 joins a ring 
atom an unsaturated bond or is a nitrogen, R20 is absent, and 
when A7 joins a ring atom an unsaturated bond and is a 
nitrogen, both R 16 and R 20 are absent. 
A 8 is carbon or nitrogen, provided that when A 8 joins a ring 
atom an unsaturated bond or is a nitrogen, R21 is absent, and 
when A8 joins a ring atom an unsaturated bond and is a 
nitrogen, bothR17 andR21 are absent. 
4 
alkylaryl; substituted alkylaryl; arylalkyl; substituted aryla-
lkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl; substi-
tuted arylalkynyl; heterocyclic; substituted heterocyclic; 
halo; cyano; nitro; SOY1 , S02Y 1 , S02 0Y1 or S02NHY1 , 
where Y 1 is selected from hydrogen, lower alkyl, alkenyl, 
alkynyl or aryl, and where Y 1 is not hydrogen in SOY1 and if 
Y 1 is alkenyl or alkynyl, the site ofunsaturation is not conju-
gated with a heteroatom; COY2 , where Y2 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
10 cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substitutedarylalkyl, arylalkenyl, substi-
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het-
erocyclic, or substituted heterocyclic, and where ifY2 com-
15 prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the carbonyl group; OY3 , where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi-
20 tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy-
clic, or substituted heterocyclic, where ifY3 comprises alk-
enyl or alkynyl, the site of unsaturation is not conjugated with 
25 the oxygen; NY4Ys, where Y4 and ys are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi-
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
30 substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy-
clic, or substituted heterocyclic, where ifY4 or ys comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
with the nitrogen; SY6 , where Y6 is selected from hydrogen, 
35 alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla-
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk-
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or 
40 substituted heterocyclic, and where ifY6 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated with the 
sulfur; or R4 and Rs together with A 1 and A2 , or Rs and R6 
togetherwithA2 andA3 , or R1s andR16 togetherwithA6 and 
A7 , or R16 and R17 together with A7 and A 8 independently 
45 form a three to eight member cyclolkane, substituted cycloal-
kane, cycloalkene, substituted cycloalkene, aryl, substituted 
aryl, heterocycle with one to three hetero atoms in the ring, or 
substituted heterocycle with one to three hetero atoms in the 
50 
ring. 
In another embodiment, describes tris-quaternary ammo-
nium compounds as described above which are modulators of 
nociception and pain. 
A9 is carbon or nitrogen, provided that whenA9 joins a ring 55 
atom an unsaturated bond or is a nitrogen, R22 is absent, and 
when A9 joins a ring atom an unsaturated bond and is a 
nitrogen, both R 18 and R 22 are absent. 
In another embodiment, a composition is provided com-
prising a pharmaceutically acceptable carrier and a com-
pound as described above. 
In another embodiment, a method is provided for prevent-
ing and/or treating nociception and pain and associated dis-
orders comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
R14 or R23 is absent when any of the bonds to the ammo-
nium nitrogen is unsaturated, and R 14 orR 23 is a straight chain 60 
or branched alkyl group of four carbons or fewer when all of 
the bonds to the ammonium nitrogen are saturated. 
R4 , Rs, R6 , R7 , R8 , R9 , R10, R11 , R12, andR13 orR1s, R16, 
R17, R18, R19, R20 , R21 , and R22 , when present, are each 
independently selected from hydrogen; alkyl; substituted 65 
alkyl; cycloalkyl; substituted cycloalkyl; alkenyl; substituted 
alkenyl; alkynyl; substituted alkynyl; aryl; substituted aryl; 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included within this description, be within the 
scope of the present invention, and be protected by the accom-
parrying claims. 
US 9,155,733 B2 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the time curve of the effect of G Z-5 5 6A in the 
Rodent Formalin Tonic Pain model following intraperitoneal 
administration. Data are mean±SEM, n=3. 
6 
The term "alkylaryl" refers to alkyl-substituted aryl 
groups, and "substituted alkylaryl" refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term "arylalkyl" refers to aryl-substituted alkyl 
groups, and "substituted arylalkyl" refers to arylalkyl groups 
further bearing one or more substituents as set forth above. FIG. 2 shows the dose response of the effectofGZ-556Ain 
Phase 1 and 2 of the Rodent Formalin Tonic Pain model 
following intraperitoneal administration. Data are 
mean±SEM, n=3. 
The term "arylalkenyl" refers to aryl-substituted alkenyl 
groups, and "substituted arylalkenyl" refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
10 
above. Before the present compositions and methods are described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these can vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 15 
is in no way intended to limit the scope of the present inven-
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms "a," "an," and "the" include plural 
references unless the context clearly dictates otherwise. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of ordinary skill in the art to which this invention 
belongs. All publications cited herein are incorporated herein 
20 
The term "arylalkynyl" refers to aryl-substituted alkynyl 
groups, and "substituted arylalkynyl" refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term "heterocyclic" refers to cyclic moieties contain-
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term "acyl" refers to alkyl-carbonyl groups, and "sub-
stituted acyl" refers to acyl groups further bearing one or 
more substituents as set forth above. 
The term "halogen" refers to fluoride, chloride, bromide or 
iodide groups. 
It is understood that in all substituted groups defined above, 
polymers arrived at by defining substituents with further sub-
stituents to themselves (e.g. substituted aryl having a substi-
tuted aryl group as a substituent which is itself substituted 
by reference in their entirety for the purpose of describing and 25 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection with the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 30 with a substituted aryl group, etc.) are not intended for inclu-
sion herein. In such cases, the maximum number of such 
substituents is three. That is to say that each of the above 
definitions is constrained by a limitation that, for example, 
substituted aryl groups are limited to -substituted aryl-(sub-
The term "agonist" refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term "partial agonist" refers to a substance which 
interacts with and activates a receptor to a lesser degree than 35 
an agonist. 
The term "antagonist" refers to a substance which interacts 
with and decreases the extent or duration of a physiological 
response of that receptor. 
The terms "disorder," "disease," and "condition" are used 40 
inclusively and refer to any status deviating from normal. 
The term "lower alkyl" refers to straight or branched chain 
alkyl radicals having in the range of 1 to 4 carbon atoms. 
The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 45 
refers to alkyl radicals further bearing one or more substitu-
ents including, but not limited to, hydroxy, alkoxy (of a lower 
alkyl group), mercapto (of a lower alkyl group), aryl, hetero-
cyclic, halogen, trifluoromethyl, cyano, nitro, amino, car-
boxyl, carbamate, sulfonyl, and sulfonamide. 50 
The term "cycloalkyl" refers to cyclic ring-containing moi-
eties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term "alkenyl" refers to straight or branched chain 55 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and "substituted 
alkenyl" refers to alkenyl groups further bearing one or more 
substituents as set forth above. 
The term "alkynyl" refers to straight or branched chain 60 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and "substituted 
alkynyl" refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term "aryl" refers to aromatic groups having 6 to 24 65 
carbon atoms, and "substituted aryl" refers to aryl groups 
further bearing one or more substituents as set forth above. 
stituted aryl)-substituted aryl. 
Compounds of the present invention are tris-quaternary 
ammonium salts corresponding to Formula (I): 
(I) 
The three side chains attached to the phenyl ring can be 
connected to the 1, 2, and3 positions; the 1, 2, and4 positions; 
or the 1, 3 and 5 positions of the phenyl ring. 
The values for m1, m2 and m3 are each independently 0, 1, 
2, 3, 4 or 5. 
The values for n1, n2, and n3 are each independently 1, 2, 
3, 4 or 5. 
X18, X28, and X38 are each independently an organic or 
inorganic anion. 
U, L2 and L3 are each independently chosen from the 
group consisting of ---CH2---CH2-, cis -CH=CH-, 
trans ---CH=CH-, -C C-, ---CH2-S-, 
-S-CH2-, -Se-CH2-, ---CH2-Se-, ---CH2---0-, 
---O-CH2-, -CH2-NH-, -NH---CH2-, ---CH2-
NR- where R is a branched or straight chain alkyl group of 
one to four carbons, -NR---CH2- where R is a branched or 
straight chain alkyl group of one to four carbons, 
---CH=N-,-N=CH-,and-N N-. 
R 1 , R 2 , and R3 are each independently five or six membered 
nitrogen containing rings as shown in formulas (IIA) and 
(liB). 
US 9,155,733 B2 
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(IIA) 
8 
where Y1 is selected from hydrogen, lower alkyl, alkenyl, 
alkynyl or aryl, and where Y1 is not hydrogen in SOY1 and if 
Y1 is alkenyl or alkynyl, the site ofunsaturation is not conju-
gated with a heteroatom; COY2 , where Y2 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substitutedarylalkyl, arylalkenyl, substi-
(liB) 10 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het-
erocyclic, or substituted heterocyclic, and where ifY2 com-
prises alkenyl or alkynyl, the site of unsaturation is not 
A 1 is carbon or nitrogen, provided that when A 1 joins a ring 
atom with an unsaturated bond or is a nitrogen, R9 is absent, 
and when A 1 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R4 and R9 are absent. 
A 2 is carbon or nitrogen, provided that when A 2 joins a ring 
atom with an unsaturated bond or is a nitrogen, RIO is absent, 
and when A 2 joins a ring atom with an unsaturated bond and 
is a nitrogen, both Rs and RIO are absent. 
A3 is carbon or nitrogen, provided that whenA3 joins a ring 
atom with an unsaturated bond or is a nitrogen, R 11 is absent, 
and when A3 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R 6 and R 11 are absent. 
A 4 is carbon or nitrogen, provided that when A 4 joins a ring 
atom with an unsaturated bond or is a nitrogen, R 12 is absent, 
and when A 4 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R 7 and R 12 are absent. 
As is carbon or nitrogen, provided thatwhenAs joins a ring 
atom with an unsaturated bond or is a nitrogen, R 13 is absent, 
and when As joins a ring atom with an unsaturated bond and 
is a nitrogen, both R 8 and R 13 are absent. 
A 6 is carbon or nitrogen, provided that when A 6 joins a ring 
atom with an unsaturated bond or is a nitrogen, R 19 is absent, 
and when A 6 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R 1s and R 19 are absent. 
conjugated with the carbonyl group; OY3 , where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
15 substituted alkynyl, aryl, substituted aryl, alkylaryl, substi-
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy-
clic, or substituted heterocyclic, where ifY3 comprises alk-
20 enyl or alkynyl, the site of unsaturation is not conjugated with 
the oxygen; NY4Ys, where Y4 and ys are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi-
25 tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy-
clic, or substituted heterocyclic, where ifY4 or ys comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
30 with the nitrogen; SY6 , where Y6 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla-
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk-
35 enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or 
substituted heterocyclic, and where ifY6 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated with the 
sulfur; or R4 and Rs together with A1 and A2 , or Rs and R6 
togetherwithA2 andA3 , or R1s andR16 togetherwithA6 and 
40 A7 , or R16 and R17 together withA7 andA8 independently 
form a three to eight member cyclolkane, substituted cycloal-
kane, cycloalkene, substituted cycloalkene, aryl, substituted 
aryl, heterocycle with one to three hetero atoms in the ring, or A 7 is carbon or nitrogen, provided that when A 7 joins a ring 
atom with an unsaturated bond or is a nitrogen, R 20 is absent, 
and when A 7 joins a ring atom with an unsaturated bond and 45 
is a nitrogen, both R16 and R20 are absent. 
substituted heterocycle with one to three hetero atoms in the 
ring. 
For example, R1 , R2 , and R3 include pyrrole, pyrrolidine, 
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, 
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet-
rahydroisoquinoline, pyrazine, piperazine, pyridazine, and 
A 8 is carbon or nitrogen, provided that when A 8 joins a ring 
atom with an unsaturated bond or is a nitrogen, R21 is absent, 
and when A 8 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R17 and R21 are absent. 50 triazine. 
A9 is carbon or nitrogen, provided that whenA9 joins a ring 
atom with an unsaturated bond or is a nitrogen, R 22 is absent, 
and when A9 joins a ring atom with an unsaturated bond and 
is a nitrogen, both R18 and R22 are absent. 
R14 or R23 is absent when any of the bonds to the ammo- 55 
nium nitrogen is unsaturated, and R 14 orR 23 is a straight chain 
or branched alkyl group of four carbons or fewer when all of 
the bonds to the ammonium nitrogen are saturated. 
R4 Rs, R6 , R7 , R8 , R9 , RIO, R11 , R12, and R13 or R1s, R16, 
R17, R18, R19, R20 , R21 , and R22 , when present, are each 60 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla-
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi- 65 
tuted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, SOY1 , S02Y1 , S02 0Y1 or S02NHY1 , 
As another example, R4 Rs, R6 , R7 , R8 , R9 , RIO, R11 , R12, 
and R13 or R1s, R16, R17, R18, R19, R20 , and R22 , include 
hydrogen, methyl, ethyl, propyl, butyl, trifluoromethyl, pyr-
rolidine, N-alkyl pyrrolidine (for example where the alkyl 
chain is methyl, ethyl or propyl), unsaturated pyrrolidine, 
unsaturated N-alkyl pyrrolidine (for example where the alkyl 
chain is methyl, ethyl or propyl), aziridine, N-methyl aziri-
dine, azetidine, N-methyl azetidine, unsaturated azetidine, 
unsaturated N -methyl azetidine, piperidine, N -methyl pi peri-
dine, unsaturated piperidine, unsaturated N-methyl piperi-
dine, azepane, N-methyl azepane, unsaturated azepane, 
unsaturated N-methyl azepane, azocane, N-methyl azocane, 
unsaturated azocane, unsaturated N-methyl azocane, 1-aza-
bicyclo[3.2.1]octane, 1-aza-bicyclo[2.2.1]heptane, 8-me-
thyl-8-aza-bicyclo[3.2.1]octane, 1-aza-tricyclo[3.3.1.13 .7] 
decane, methyl cycloalkyl, methyl substituted cycloalkyl, 
methylpyrrolidine, methyl N-alkyl pyrrolidine (for example 
US 9,155,733 B2 
9 10 
where the alkyl chain is methyl, ethyl or propyl), methyl In a compound of Formula (I), preferably R6 is hydrogen, 
unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrroli- alkyl, or forms an aryl ring withA2, A3 and R5. More prefer-
dine (for example where the alkyl chain is methyl, ethyl or ably, R6ishydrogen,methylorformsa phenyl groupwithA2, 
propyl), methyl aziridine, methyl N-methyl aziridine, methyl A3 and R5. 
azetidine, methyl N-methyl azetidine, methyl unsaturated 5 In a compound ofFormula (I), preferably R7 is hydrogen or 
azetidine, methyl unsaturated N-methyl azetidine, methyl alkyl. More preferably, R7 is hydrogen or methyl. 
piperidine, methyl N-methyl piperidine, methyl unsaturated In a compound of Formula (I), preferably R8 is hydrogen. 
piperidine, methyl unsaturated N-methyl piperidine, methyl In a compound of Formula (I), preferably m=O. 
azepane, methyl N-methyl azepane, methyl unsaturated In a compound of Formula (I), preferably n=3. 
azepane, methyl unsaturated N-methyl azepane, methyl azo- 10 In a compound of Formula (I), preferably L 1, L 2 and L3 are 
cane, methy IN-methy I azocane, methy I unsaturated azocane, ---CH2---CH2- or -C===C-. 
methyl unsaturatedN-methyl azocane, methyl-1-aza-bicyclo In a compound of Formula (I), preferably X18, X2 8 , and 
[3.2.1]octane, methyl-1-aza-bicyclo[2.2.1]heptane, 8-me- X38 are halogens. More preferably, X18, X28, and X38 are 
thyl-8-aza-bicyclo[3.2.1]octane, and methyl-1-aza-tricyclo 15 bromide. [3.3.1.13.7]decane. In one embodiment, the compound of Formula (I) is 
As a further example, when R4 and R5 togetherwithA 1 and defined wherein the phenyl ring is 1 ,3,5 substituted; wherein 
A2, or R5 and R6 together withA2 andA3, or R15 and R16 m=O;whereinn=3;whereinLis-CH2CH2-or---C C-; 
togetherwithA6 andA7, or R16 andR17 togetherwithA7 and wherein R\ R2, and R3 are pyridinium rings; wherein R4 is 
A8 independently form a three to eight-membered ring, that 20 hydrogen,methylorformsaphenylgroupwithA1,A2 andR5; 
ring can be a heterocycle containing up to three hetero atoms wherein R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2-
(for example nitrogen, oxygen or sulfur) in the ring, and pyrrolidinyl, forms a phenyl group with A\ A2 and R4, or 
further can be substituted with one or more substituents. For forms a phenyl group with A2, A3 and R6; wherein R6 is 
example, possible rings include benzene, pyridine, pyran, hydrogen,methylorformsaphenylgroupwithA2,A3 andR5; 
indene, isoindene, benzofuran, isobenzofuran, benzo[b] 25 and wherein X\ X2, and X3 are Br. 
thiophene, benzo[ c ]thiophene, indole, indolenine, isoindole, In another embodiment, the compound of Formula (I) is 
cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, indazole, defined wherein the phenyl ring is 1 ,3,5 substituted; wherein 
indoxazine, benzoxazole, anthranil naphthalene, tetralin, m=O; wherein n=3; wherein L is -CH2CH2-; wherein R 1, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, R2, and R3 are pyridinium rings; wherein R4 is hydrogen, 
isochromen-3-one, quinoline, isoquinoline, cinnoline, 30 methyl or forms a phenyl group with A 1, A2 and Rs; wherein 
quinazoline, naphthyrdine, pyrido[3,4-b ]-pyridine, pyridol Rs is hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidi-
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benzoxazine, nyl, forms a phenyl group with A\ A2 and R4, or forms a 
anthracene, phenanthrene, phenalene, fluorene, carazole, phenyl group with A2, A3 and R6; wherein R6 is hydrogen, 
xanthene, acnidine, octahydro-[1]pyridine, 1-methyloctahy- methyl or forms a phenyl group with A2, A3 and Rs; and 
dro-[1]pyridine, octahydroindole, 1-methyloctahydro-in- 35 whereinXl, X2, andX3 are Br. 
dole, octahydro-cyclopenta[b ]pyrrole, 1-methyloctahydro-
cyclopenta[b ]pyrrole, decahydroquinoline, and In another embodiment, the compound of Formula (I) is defined wherein the phenyl ring is 1 ,3,5 substituted; wherein 
1-methyldecahydroquinoline. m=O; wherein n=3; wherein L is ---C C-; wherein R 1, R 2, 
X
18
, X
28
, and X
38
' for example, include F-, c!-, Br-, I-, and R3 are pyridinium rings; wherein R4 is hydrogen, methyl 
N02-, HS04-, S04-, HP04-, P042-, methanesulfonate, trif- 40 or forms a phenyl group withAl, A2 and Rs; wherein Rs is 
luoromethane sulfate, p-toluenesulfonate, benzenesulfonate, 
salicylate, proprionate, ascorbate, aspartate, fumarate, galac- hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidinyl, 
forms a phenyl group withA1, A2 and R4, or forms a phenyl 
tarate, maleate, citrate, glutamate, glycolate, lactate, malate, group with A 2' A3 and R 6; wherein R 6 is hydrogen, methyl or 
maleate, tartrate, oxalate, succinate, or similar pharmaceuti- 2 3 5 1 2 formsaphenylgroupwithA ,A andR ;andwhereinX ,X, 
cally acceptable organic acid addition salts, including the 45 and X3 are Br. 
pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences volume 66, page 2, 1977, which are 
hereby incorporated by reference. The above salt forms can 
be in some cases hydrates or solvates with alcohols and other 
solvents. 50 
In a compound of Formula (I), preferably the phenyl ring is 
substituted at the 1, 3 and 5 positions. 
In a compound of Formula (I), preferably A1, A2, A3, A4, 
andA5 are carbon. 
In a compound of Formula (I), preferably R1, R2, and R3 55 
are substituted, six-membered, aromatic rings. More prefer-
ably, R\ R2, and R3 are substituted pyridinium rings. 
In a compound of Formula (I), preferably R4 is hydrogen, 
alkyl, or forms an aryl ring withA1, A2 and R5. More prefer-
ably, R4 is hydrogen, methyl or forms a phenyl group with A 1, 60 
A2 andR5. 
In a compound of Formula (I), preferably R5 is hydrogen, 
alkyl, phenyl, 1-methyl-2-pyrrolidinyl, forms a six-mem-
bered ring withA1,A2 and R4, or forms an aryl ring withA2, 
A3 and R6. More preferably, R5 is hydrogen, methyl, butyl, 65 
phenyl, 1-methyl-2-pyrrolidinyl, forms a phenyl group with 
A1, A2 and R4, or forms a phenyl group withA2, A3 and R6. 
An exemplary compound for this application is presented 
below: 
e 
3 Br 
The compounds of the present invention can contain one or 
more stereocenters. The invention includes all possible dias-
tereomers and all enantiomeric forms as well as racemic 
mixtures. The compounds can be separated into substantially 
optically pure compounds. 
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Central nervous system disorders which can be treated 
according to the method of the present invention include 
disorders of nociception, and pain. 
In yet another embodiment, the present invention is 
directed to a method for preventing pain, comprising admin-
istering to a mammalian subject in need thereof a therapeu-
tically effective amount of a compound of Formula (I). In 
such a method, the compound of Formula (I) can reduce a 
pain response. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along with suit-
able carriers or excipients, as is well known in the art. For 
example, a pharmaceutical composition of the invention can 
include a conventional additive, such as a stabilizer, buffer, 
salt, preservative, filler, flavor enancer and the like, as known 
to those skilled in the art. Exemplary buffers include phos-
phates, carbonates, citrates and the like. Exemplary preserva-
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter-
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro-
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington's Pharmaceutical Sciences. 
Suitable routes of administration can, for example, include 
oral, rectal, transmucosal, nasal, or intestinal administration 
and parenteral delivery, including intramuscular, subcutane-
ous, intramedullary injections, as well as intrathecal, direct 
intraventricular, intravenous, intraperitoneal, intranasal, or 
intraocular injections. In addition, the agent or composition 
thereof can be administered sub lingually or via a spray. The 
agent or composition thereof can be administered in a local 
rather than a systemic manner. For example, a suitable agent 
can be delivered via injection or in a targeted drug delivery 
system, such as a depot or sustained release formulation. 
12 
Pharmaceutical preparations for oral use can be obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux-
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
excipients are, in particular, fillers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maize starch, wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel-
10 lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin-
tegrating agents can be added, such as the cross-linked poly-
vinylpyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, wetting agents such as sodium dodecyl 
15 sulfate can be included. 
Dragee cores are provided with suitable coatings. For this 
purpose, concentrated sugar solutions can be used, which can 
optionally contain gum arabic, talc, polyvinyl pyrrolidone, 
carbopol gel, polyethylene glycol, and/or titanium dioxide, 
20 lacquer solutions, and suitable organic solvents or solvent 
mixtures. Dyestuffs or pigments can be added to the tablets or 
dragee coatings for identification or to characterize different 
combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
25 include push-fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-fit capsules can contain the 
active ingredients in admixture with filler such as lactose, 
binders such as starches, and/or lubricants such as talc or 
30 
magnesium stearate and, optionally, stabilizers. In soft cap-
sules, the active compounds can be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraffin, or liquid 
polyethylene glycols. In addition, stabilizers can be added. 
35 All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven-
The pharmaceutical compositions of the present invention 
can be manufactured by any of the methods well-known in the 
art, such as by conventional mixing, dissolving, granulating, 40 
dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophilizing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 45 
into preparations for pharmaceutical use. 
tion can be administered transdermally, such as through a skin 
patch, or micro-needle patch, or topically. In one aspect, the 
transdermal or topical formulations of the present invention 
can additionally comprise one or multiple penetration 
enhancers or other effectors, including agents that enhance 
migration of the delivered compound. Trans dermal or topical 
administration could be preferred, for example, in situations 
in which location specific delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, with the use of a suitable propellant, e.g., 
dichlorodifluoromethane, trichlorofluoromethane, dichlo-
rotetrafluoroethane, carbon dioxide, or any other suitable gas. 
Proper formulation is dependent upon the route of admin-
istration chosen. For injection, for example, the composition 
can be formulated in aqueous solutions, preferably in physi-
ologically compatible buffers such as Hanks' solution, Ring- 50 
er's solution, or physiological saline buffer. Fortransmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally known in the art. In a preferred embodiment of 
55 
the present invention, the present compounds are prepared in 
In the case of a pressurized aerosol, the appropriate dosage 
unit can be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insufflator can be formulated. 
These typically contain a powder mix of the compound and a 
suitable powder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e.g., by bolus injection or continuous infusion can 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
combining the active compounds with pharmaceutically 
acceptable carriers well known in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen-
sions and the like, for oral ingestion by a subject. The com-
pounds can also be formulated in rectal compositions such as 
60 be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The com-
positions can take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and can contain for-
suppositories or retention enemas, e.g., containing conven- 65 
tiona! suppository bases such as cocoa butter or other glyc-
erides. 
mulatory agents such as suspending, stabilizing and/or dis-
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in water-
soluble form. 
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Suspensions of the active compounds can also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer-
ides, or liposomes. Aqueous injection suspensions can con-
tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension can also contain suitable stabiliz-
ers or agents that increase the solubility of the compounds to 
allow for the preparation of highly concentrated solutions. 10 
Alternatively, the active ingredient can be in powder form for 
constitution with a suitable vehicle, e.g., sterile pyrogen-free 
water, before use. 
As mentioned above, the compositions of the present 
invention can also be formulated as a depot preparation. Such 15 
long acting formulations can be administered by implantation 
(for example, subcutaneously or intramuscularly) or by intra-
muscular injection. Thus, for example, the present com-
pounds can be formulated with suitable polymeric or hydro-
phobic materials (for example as an emulsion in an acceptable 20 
oil) or ion exchange resins, or as sparingly soluble deriva-
tives, for example, as a sparingly soluble salt. 
14 
Toxicity and therapeutic efficacy of such molecules can be 
determined by standard pharmaceutical procedures in cell 
cultures or experimental animals, e.g., by determining the 
LD50 (the dose lethal to 50% of the population) and the ED 5 0 
(the dose therapeutically effective in 50% of the population). 
The dose ratio of toxic to therapeutic effects is the therapeutic 
index, which can be expressed as the ratio LD 50/ED 50 . Agents 
that exhibit high therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating con-
centrations that includes the ED50 with little or no toxicity. 
Dosages can vary within this range depending upon the dos-
age form employed and the route of administration utilized. 
The exact formulation, route of administration, and dosage 
should be chosen, according to methods known in the art, in 
view of the specifics of a subject's condition. 
The amount of agent or composition administered will, of 
course, be dependent on a variety of factors, including the sex, 
age, and weight of the subject being treated, the severity of the 
affliction, the mauner of administration, and the judgment of 
the prescribing physician. 
The present compositions can, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aqueous 
phase. The co-solvent system can be the VPD co-solvent 
system. VPD is a solution of3% w/v benzyl alcohol, 8% w/v 
25 forms containing the active ingredient. Such a pack or device 
can, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device can be accompa-
nied by instructions for administration. Compositions com-
prising a compound of the invention formulated in a compat-of the nonpolar surfactant polysorbate 80, and 65% w/v poly-
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (VPD:5 W) consists of VPD 
diluted 1:1 with a 5% dextrose in water solution. This co-
solvent system is effective in dissolving hydrophobic com-
pounds and produces low toxicity upon systemic administra-
tion. Naturally, the proportions of a co-solvent system can be 35 
varied considerably without destroying its solubility and tox-
icity characteristics. Furthermore, the identity of the co-sol-
vent components can be varied. For example, other low-
toxicity nonpolar surfactants can be used instead of 
polysorbate 80, the fraction size of polyethylene glycol can be 40 
varied, other biocompatible polymers can replace polyethyl-
ene glycol, e.g., polyvinyl pyrrolidone, and other sugars or 
polysaccharides can substitute for dextrose. 
30 ible pharmaceutical carrier can also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi-
cated condition. 
Alternatively, other delivery systems for hydrophobic mol-
ecules can be employed. Liposomes and emulsions are well 45 
known examples of delivery vehicles or carriers for hydro-
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also can be 
employed, although usually at the cost of greater toxicity. 50 
Additionally, the compounds can be delivered using sus-
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained-
release materials are established and available to those of skill 55 
in the art. Sustained-release capsules can, depending on their 
chemical nature, release the compounds for a few weeks up to 
over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabilization can be employed. 60 
For any composition used in the present methods of treat-
ment, a therapeutically effective dose can be estimated ini-
tially using a variety of techniques well known in the art. 
Dosage ranges appropriate for human subjects can be deter-
mined, for example, using data obtained from animal studies. 65 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms. 
These and other embodiments of the present invention will 
readily occur to those of ordinary skill in the art in view of the 
disclosure herein, and are specifically contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
following example, which is intended to be purely exemplary 
of the invention. The present invention is not limited in scope 
by the exemplified embodiment, which is intended as an 
illustration of a single aspect of the invention only. Any meth-
ods that are functionally equivalent are within the scope of the 
invention. Various modifications of the invention in addition 
to those described herein will become apparent to those 
skilled in the art from the foregoing description. Such modi-
fications fall within the scope of the appended claims. 
Example 1 
Preparation of 
1 ,3,5-tris-(5-hydroxypent-1-ynyl)-benzene 
15 
-continued 
HO 
OH 
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1 ,3,5-tris-(5-hydroxy-1-pentynyl)benzene (2.84 g, 8.6 
mmol) was dissolved in methanol (30 mL) and 10% Pd!C (5% 
w/w) was added. The resulting mixture was hydrogenated on 
5 a Parr hydrogenation apparatus (45 psi) for 4 hours. The 
catalyst was removed by filtration through a celite pad. The 
filter cake was rinsed with methanol, and the combined 
organic liquors were concentrated under reduced pressure. 
10 The crude product was purified by colunm chromatography 
(CHCI3 :MeOH 6:1) to afford 2.84 g of 1 ,3,5-tris-(5-hydroxy-
pentyl)benzene. Yield 96%. 1H NMR (300 MHz, CDCI3 ) o 
6.81 (s, 3H), 3.62 (t, 1=6.3 Hz, 6H), 2.57 (t, 1=7.5 Hz, 6H), 
15 1.53-1.70 (m, 12H), 1.38 (m, 6H) ppm; 13C NMR (75 MHz, 
CDCI3 ) o142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm. 
1,3,5-Tribromobenzene (10 g, 31.76 mmol), 4-pentyn-1-ol 
(10.69 g, 127.06 mmol) and bis(triphenylphosphine)palla-
dium(II) dichloride were stirred in triethylamine under nitro- 20 
gen for 5 minutes. Copper(!) iodide (92 mg, 0.48 mmol) was 
added and the mixture was stirred for 6 hours at 80° C. The 
mixture was cooled to room temperature, filtered through a 
celite pad and rinsed with ethyl acetate. The combined filtrate 25 
was evaporated to dryness under reduced pressure. The 
resulting residue was purified by column chromatography 
(CHCI3 :MeOH 10:1) to afford 7.61 g of 1,3,5-tris-(5-hy-
droxy-1-pentynyl)benzene. Yield: 74%. 1 H NMR (300 MHz, 30 
CDCI3 ) o7.31 (3, 3 h), 3.81 (t, 1=6.0 Hz, 6H), 2.52 (t, 1=6.9 
Hz, 6H), 1.85 (m, 6H); 13C NMR (7 5 MHz, CDCI3 ) o 133 .8, 
124.2, 90.5, 80.0, 61.9, 31.5, 16.2 ppm. 
HO 
Example 3 
Preparation of 1,3,5-tris-(5-bromopentyl)benzene 
OH 
OH 
Example 2 
Preparation of 1 ,3,5-tris-(5-hydroxypentyl)benzene 
HO 
HO 
35 
40 
45 
50 
55 
Br Br 
1,3,5-tris-(5-hydroxypentyl)benzene (2.83 g, 8.41 mmol) 
and carbon tetrabromide (10.99 g, 32.80 mmol) were dis-
solved in dry methylene chloride (50 mL) and cooled to oo C. 
Triphenylphosphine (9.03 g, 34.33 mmol) was added drop-
wise and the mixture was stirred for 30 minutes at oo C. The 
OH mixture was poured into hexanes (250 mL ), filtered through a 
short silica gel colunm and washed with ethy I acetatelhexanes 
(1/4). The combined organic solvents were evaporated to 
60 
dryness under reduced pressure. The resulting residue was 
purified by column chromatography (hexanes:ethyl acetate 
8:1) to afford 4.08 g of 1,3,5-tris-(5-bromopentyl)-benzene. 
Yield 92%. 1H NMR (300 MHz, CDCI3 ) o6.81 (s, 3 h), 3.41 
65 
(t, 1=6.9 Hz, 6H), 2.60 (t, 1=7.5 Hz, 6H), 1.88 (m, H), 1.45 (m, 
6H) ppm; 13C NMR (75 MHz, CDCI3 ) o142.4, 126.1, 35.9, 
34.2, 32.9, 30.9, 28.2 ppm. 
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Example 4 
Preparation of 
1 ,3,5-tris-[ 5-(1-quinolinium)pentyl]benzene 
tribromide 
Br 
Br 
C(5 8 I ::::::... I # 
8 e 3 Br # 
10 
20 
25 
30 
A mixture of 1 ,3,5-tris-(5-bromopentyl)benzene (251 mg, 
0.48 mmol) and quinoline (930 mg, 7.20 mmol) was heated at 
60-70° C. for 12 hours. The resultant mixture was washed 
with diethyl ether and then dissolved in water (15 mL), the 35 
aqueous solution was washed with diethyl ether (30 mLx5), 
then lyophilized to afford 390 mg of 1,3,5-tris-[5-(1-quino-
linium)pentyl]-benzene tribromide. Yield 89%. 1H NMR 
(300 MHz, CD3 0D) o 9.46 (dd, 1=6.0, 1.5 Hz, 3H), 9.22 (d, 
1 8.4 Hz, 3H), 8.57 ( d, 1=9.0 Hz, 3H), 8.45 ( dd, 1=8.4, 1.5 Hz, 40 
3H), 8.30 (m, 3H), 8.02-8.14 (m, 6H), 6.8 (s, 3H), 5.11 (t, 7.5 
Hz, 6H), 2.56 (t, 1=7.5 Hz, 6H), 2.14 (m, 6H), 1.69 (m, 6H), 
1.52 (m, 6H) ppm; 13C NMR (75 MHz, CD30D) o 150.3, 
148.9, 143.4, 139.4, 137.3, 132.2, 131.8, 131.4, 127.2, 123.1, 
119.9, 59.4, 36.7, 32.3, 31.1, 27.3 ppm. 
Example 5 
A rat model of tonic inflammatory pain (the formalin test) 
was used in this study (Wheeler-Aceta and Cowan, 1991). 50 
Fifty fll offormalin (5%) was injected subcutaneously (SC) 
into the dorsal surface of the left hind paw. This procedure 
typically produces a biphasic behavioral response consisting 
of flinching, lifting and licking. The first phase (0-10 min) is 
thought to result from direct stimulation of nociceptors (noci- 55 
ceptive pain) whereas the second phase (20-60 min) is 
thought to involve central sensitization. Rats ( 4-8/dose/treat-
ment) were pretreated 15 min prior to formalin (SC) injection 
with GZ-556A (90-180 mg/kg) administered by the IP route. 
Saline served as control. Incidences of formalin-induced 60 
flinching were counted continuously in 5 min intervals for 60 
min. Each rat received only one treatment. The results are 
presented in FIGS. 1 and 2. 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications can be made without 
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departing from the spirit and scope of the invention. All such 
modifications and variations are intended to be included 
herein within the scope of this disclosure and the present 
invention and protected by the following claims. 
What is claimed is: 
1. A method for treating neuropathic pain resulting from 
damage to the peripheral nervous system, comprising admin-
istering to a mammalian subject in need thereof a therapeu-
tically effective amount of a compound of Formula (I): 
(I) 
wherein 
the three side chains attached to the phenyl ring are con-
nected to the 1, 3 and 5 positions of the phenyl ring; 
m1, m2 and m3 are each 0; 
n1, n2, and n3 are each 3; 
X18, X28, and X38 are each independently an organic or 
inorganic anion; 
L 1 , L 2 and L3 are each -CH2-CH2-; 
R 1 , R 2 , and R3 are each quinolinium or isoquinolinium and 
attached to (CH2 )nu (CH2)n2 , or (CH2 )n3 at the quater-
nized nitrogen of the quinolinium or isoquinolinium. 
2. The method of claim 1, wherein the compound of For-
mula (I) is 1,3,5-tris-[5-(1-quinolinium)-pentyl]-benzene tri-
bromide. 
3. The method of claim 1, wherein the pain is chronic. 
4. The method of claim 1, wherein the pain is cancer-
related pain. 
5. The method of claim 1, wherein the pain is non-malig-
nant pain. 
6. A method for treating inflammatory pain resulting from 
activation of peripheral nociceptor, comprising administering 
to a mammalian subject in need thereof a therapeutically 
effective amount of a compound of Formula (I): 
(I) 
wherein 
the three side chains attached to the phenyl ring are con-
nected to the 1, 3 and 5 positions of the phenyl ring; 
m1, m2 and m3 are each 0; 
n1, n2, and n3 are each 3; 
X18, X28, and X38 are each independently an organic or 
inorganic anion; 
L 1 , L 2 and L3 are each -CH2-CH2-; 
R 1 , R 2 , and R3 are each quinolinium or isoquinolinium and 
attached to (CH2 )n 1 . (CH2)n2 , or (CH2 )n3 at the quater-
nized nitrogen of the quinolinium or isoquinolinium. 
7. The method of claim 6, wherein the compound of For-
mula (I) is 1,3,5-tris-[5-(1-quinolinium)-pentyl]-benzene tri-
bromide. 
* * * * * 
